Adults Only Really Catch Flu About Twice a Decade, Suggests Study
News Mar 05, 2015
Adults over the age of 30 only catch flu about twice a decade, a new study suggests.
Flu-like illness can be caused by many pathogens, making it difficult to assess how often people are infected by influenza.
Researchers analyzed blood samples from volunteers in Southern China, looking at antibody levels against nine different influenza strains that circulated from 1968 to 2009.
They found that while children get flu on average every other year, flu infections become less frequent as people progress through childhood and early adulthood. From the age of 30 onwards, flu infections tend to occur at a steady rate of about two per decade.
Dr Adam Kucharski, who worked on the study at Imperial College London before moving to the London School of Hygiene & Tropical Medicine, said: "There's a lot of debate in the field as to how often people get flu, as opposed to flu-like illness caused by something else. These symptoms could sometimes be caused by common cold viruses, such as rhinovirus or coronavirus. Also, some people might not realize they had flu, but the infection will show up when a blood sample is subsequently tested. This is the first time anyone has reconstructed a group's history of infection from modern-day blood samples."
Dr Steven Riley, senior author of the study, from the Medical Research Council Centre for Outbreak Analysis and Modelling at Imperial, said: "For adults, we found that influenza infection is actually much less common than some people think. In childhood and adolescence, it's much more common, possibly because we mix more with other people. The exact frequency of infection will vary depending on background levels of flu and vaccination."
In addition to estimating the frequency of flu infection, the researchers, from the UK, the US and China, developed a mathematical model of how our immunity to flu changes over a lifetime as we encounter different strains of the virus.
The immune system responds to flu viruses by producing antibodies that specifically target proteins on the virus surface. These proteins can change as the virus evolves, but we keep antibodies in the blood that have a memory for strains we've encountered before.
The model supported evidence from other studies that the strains of influenza virus we encounter earlier in life evoke stronger immune responses than those we meet later.
The findings will help take into account the effect of immunity in the population on the evolution of flu viruses, and potentially make predictions about how the virus will change in the future. They could also help scientists consider how immunity to historical strains will influence the way vaccines work and how effective they will be.
Dr Kucharski said: "What we've done in this study is to analyze how a person's immunity builds up over a lifetime of flu infections. This information helps us understand the susceptibility of the population as a whole and how easy it is for new seasonal strains to spread through the population."
The findings are published in PLOS Biology. Funding for the research came from the Medical Research Council, the Wellcome Trust, the National Institute for Health Research Health Protection Research Unit in Respiratory Infections at Imperial College London in partnership with Public Health England, the Fogarty International Centre, the US Department of Homeland Security, and the National Institute for General Medical Sciences.
Cobra Biologics Awarded £2.6m ($3.4m USD) from Innovate UKNews
Capital infrastructure investment to embed and secure clinical and commercial viral vector manufacturing capability within the UK. Award made as part of UK’s Innovation Agency’s Industrial Strategy boost for UK medicines with £70m of funding to help develop new treatments.READ MORE
Latent HIV Reservoirs Inherently Resistant to Elimination by CD8+ T-cellsNews
The latest “kick-and-kill” research to eliminate the HIV virus uncovered a potential obstacle in finding a cure. A recent study found that latent HIV reservoirs show resistance to CD8+ T-cells, a type of white blood cell whose primary function is to kill infected cells.READ MORE
LifeArc and Milner Therapeutics Institute Announce a New Partnership in AI for Target DiscoveryNews
LifeArc®, the UK-based medical research charity, and the Milner Therapeutics Institute at the University of Cambridge, today announced a new partnership to identify and validate new drug targets in immuno-oncology and respiratory diseases.READ MORE